In yesterday’s Wall Street session, ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) shares traded at $5.45, down -5.71% from the previous session.
As of this writing, 6 analysts cover ORIC Pharmaceuticals Inc. (NASDAQ:ORIC). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $16.00 and a low of $9.00, we find $15.00. Given the previous closing price of $5.78, this indicates a potential upside of 159.52 percent. ORIC stock price is now 67.04% away from the 50-day moving average and 39.62% away from the 200-day moving average. The market capitalization of the company currently stands at $178.76M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
There are 2 analysts who have given it a hold rating, whereas 3 have given it a buy rating. Brokers who have rated the stock have averaged $13.75 as their price target over the next twelve months.
On April 04, 2022, Citigroup Upgraded its previous ‘Neutral’ rating to ‘Buy’ on the stock increasing its target price from $7 to quote $10, while ‘H.C. Wainwright’ rates the stock as ‘Neutral’.
In other news, Piscitelli Dominic, Chief Financial Officer sold 2,089 shares of the company’s stock on Dec 15. The stock was sold for $6,789 at an average price of $3.25. Upon completion of the transaction, the Chief Financial Officer now directly owns 67,423 shares in the company, valued at $0.37 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 15, President and CEO Chacko Jacob sold 5,764 shares of the business’s stock. A total of $18,733 was realized by selling the stock at an average price of $3.25. This leaves the insider owning 817,025 shares of the company worth $4.45 million. A total of 2.98% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ORIC stock. A new stake in ORIC Pharmaceuticals Inc. shares was purchased by PROSIGHT MANAGEMENT, LP during the first quarter worth $5,103,000. APOGEM CAPITAL LLC invested $359,000 in shares of ORIC during the first quarter. In the first quarter, BRIDGEWAY CAPITAL MANAGEMENT, LLC acquired a new stake in ORIC Pharmaceuticals Inc. valued at approximately $353,000. BAILARD, INC. acquired a new stake in ORIC for approximately $210,000. JACOBS LEVY EQUITY MANAGEMENT, INC purchased a new stake in ORIC valued at around $132,000 in the second quarter. In total, there are 123 active investors with 83.00% ownership of the company’s stock.
Tuesday morning saw ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) opened at $5.66. During the past 12 months, ORIC Pharmaceuticals Inc. has had a low of $2.36 and a high of $16.78. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 15.00, and a quick ratio of 15.00. The fifty day moving average price for ORIC is $3.26 and a two-hundred day moving average price translates $3.90 for the stock.
The latest earnings results from ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) was released for Jun, 2022.
ORIC Pharmaceuticals Inc.(ORIC) Company Profile
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
